CIGB 2020 Uses, Dosage, Side Effects and more
CIGB 2020 is a vaccine candidate administered nasally and sublingually, working to strengthen immunity in the areas administered. The vaccine was developed and tested by the Center for Genetic Engineering and Biotechnology (CIGB), in Havana Cuba. As of July, 2020, a Randomized control clinical trial (RPCEC00000306) is underway to evaluate prophylaxis potential in suspected contacts of Covid-19 patients.
| Trade Name | CIGB 2020 |
| Generic | CIGB 2020 Vaccine |
| CIGB 2020 Vaccine Other Names | CIGB 2020 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
